Logo image of SKYE

SKYE BIOSCIENCE INC (SKYE) Stock Fundamental Analysis

NASDAQ:SKYE - Nasdaq - US83086J2006 - Common Stock - Currency: USD

1.435  -0.15 (-9.18%)

After market: 1.4302 0 (-0.33%)

Fundamental Rating

3

Taking everything into account, SKYE scores 3 out of 10 in our fundamental rating. SKYE was compared to 568 industry peers in the Biotechnology industry. While SKYE has a great health rating, there are worries on its profitability. SKYE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SKYE had negative earnings in the past year.
In the past year SKYE has reported a negative cash flow from operations.
SKYE had negative earnings in each of the past 5 years.
SKYE had a negative operating cash flow in each of the past 5 years.
SKYE Yearly Net Income VS EBIT VS OCF VS FCFSKYE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -36.51%, SKYE is in the better half of the industry, outperforming 60.21% of the companies in the same industry.
With a decent Return On Equity value of -38.98%, SKYE is doing good in the industry, outperforming 71.30% of the companies in the same industry.
Industry RankSector Rank
ROA -36.51%
ROE -38.98%
ROIC N/A
ROA(3y)-188.54%
ROA(5y)-179.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKYE Yearly ROA, ROE, ROICSKYE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SKYE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SKYE Yearly Profit, Operating, Gross MarginsSKYE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for SKYE has been increased compared to 1 year ago.
Compared to 5 years ago, SKYE has more shares outstanding
There is no outstanding debt for SKYE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SKYE Yearly Shares OutstandingSKYE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SKYE Yearly Total Debt VS Total AssetsSKYE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 2.71 indicates that SKYE is not a great score, but indicates only limited risk for bankruptcy at the moment.
SKYE has a better Altman-Z score (2.71) than 76.76% of its industry peers.
There is no outstanding debt for SKYE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACCN/A
SKYE Yearly LT Debt VS Equity VS FCFSKYE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 16.32 indicates that SKYE has no problem at all paying its short term obligations.
SKYE has a better Current ratio (16.32) than 92.43% of its industry peers.
A Quick Ratio of 16.32 indicates that SKYE has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 16.32, SKYE belongs to the best of the industry, outperforming 92.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.32
Quick Ratio 16.32
SKYE Yearly Current Assets VS Current LiabilitesSKYE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

SKYE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.22%, which is quite impressive.
EPS 1Y (TTM)87.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -30.07% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-70.12%
EPS Next 2Y-39.5%
EPS Next 3Y-36.21%
EPS Next 5Y-30.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SKYE Yearly Revenue VS EstimatesSKYE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M 400M
SKYE Yearly EPS VS EstimatesSKYE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SKYE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKYE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKYE Price Earnings VS Forward Price EarningsSKYE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SKYE Per share dataSKYE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as SKYE's earnings are expected to decrease with -36.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-39.5%
EPS Next 3Y-36.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SKYE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SKYE BIOSCIENCE INC

NASDAQ:SKYE (4/17/2025, 8:00:02 PM)

After market: 1.4302 0 (-0.33%)

1.435

-0.15 (-9.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners85.58%
Inst Owner Change0%
Ins Owners1.32%
Ins Owner Change-0.14%
Market Cap44.44M
Analysts84.62
Price Target17.68 (1132.06%)
Short Float %7.24%
Short Ratio13.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)39.04%
Min EPS beat(2)17.2%
Max EPS beat(2)60.89%
EPS beat(4)2
Avg EPS beat(4)16.81%
Min EPS beat(4)-10.29%
Max EPS beat(4)60.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.7%
PT rev (3m)-3.7%
EPS NQ rev (1m)-2.96%
EPS NQ rev (3m)-6.3%
EPS NY rev (1m)-4.94%
EPS NY rev (3m)-5.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.65
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0
BVpS2.2
TBVpS2.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.51%
ROE -38.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.54%
ROA(5y)-179.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 537.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.32
Quick Ratio 16.32
Altman-Z 2.71
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)207.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.9%
EPS Next Y-70.12%
EPS Next 2Y-39.5%
EPS Next 3Y-36.21%
EPS Next 5Y-30.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-92.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-80.89%
OCF growth 3YN/A
OCF growth 5YN/A